Sugi Predict

Sugi Predict / Compounds / SCHEMBL29908653

SCHEMBL29908653

SCHEMBL29908653

CN(C(=O)OCC1c2ccccc2-c2ccccc21)C(C)(C)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ FABP5 Q01469 3/20 0.46
▸ FABP7 O15540 2/20 0.46
▸ KMT2A Q03164 2/20 0.44
▸ EPHX2 P34913 1/20 0.41
▸ MDM4 O15151 2/20 0.40
▸ TP53 P04637 2/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29709499 1.00 FABP5 (0.46) FABP5FABP7KMT2AEPHX2MDM4
SCHEMBL118230 1.00 FABP5 (0.46) FABP5FABP7KMT2AEPHX2MDM4
SCHEMBL30215708 0.85 FABP5 (0.45) FABP5FABP7KMT2AEPHX2MDM4
SCHEMBL25657461 0.84 KMT2A (0.47) FABP5FABP7KMT2AEPHX2MDM4
SCHEMBL25185748 0.84 FABP5 (0.42) FABP5FABP7KMT2AEPHX2MDM4
SCHEMBL25178712 0.84 FABP5 (0.42) FABP5FABP7KMT2AEPHX2MDM4
SCHEMBL10037319 0.81 KMT2A (0.51) FABP5FABP7KMT2AEPHX2CASP3
SCHEMBL30584150 0.81 KMT2A (0.51) FABP5FABP7KMT2AEPHX2CASP3
SCHEMBL31370739 0.81 FABP5 (0.40) FABP5FABP7KMT2AEPHX2MDM4
SCHEMBL120280 0.80 FABP5 (0.50) FABP5FABP7KMT2AEPHX2CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 — — US disclosed
US-12404299-B2 Method for producing peptide compound comprising highly sterically hindered amino acid CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-02 — — US disclosed
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20250230193-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI PHARMACEUTICAL CO LTD (JP) 2025-07-17 — — US disclosed
US-20250051394-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-02-13 — — US disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 — — US disclosed
US-20240158446-A1 CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-16 — — US disclosed
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-09 — — US disclosed
EP-4316503-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-07 — — EP disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed
US-20230026641-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-26 — — US disclosed
EP-4056580-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS FABP5 4094/4885FABP7 4602/4885KMT2A 3145/4885
US-20240158446-A1 CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS KRAS, HRAS, NRAS FABP5 4703/4885FABP7 4408/4885KMT2A 1822/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS FABP5 4094/4885FABP7 4602/4885KMT2A 3145/4885
US-12410212-B2 Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS KRAS, HRAS, NRAS FABP5 4631/4885FABP7 4721/4885KMT2A 1250/4885
US-20230026641-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID DNPEP, VIP, NPEPPS FABP5 3048/4885FABP7 2102/4885KMT2A 2469/4885
US-20250051394-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS KRAS, HRAS, NRAS FABP5 4631/4885FABP7 4721/4885KMT2A 1250/4885
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND VIP, IAPP, KRAS FABP5 4026/4885FABP7 4376/4885KMT2A 4757/4885
US-12404299-B2 Method for producing peptide compound comprising highly sterically hindered amino acid DNPEP, VIP, NPEPPS FABP5 3048/4885FABP7 2102/4885KMT2A 2469/4885
US-20250230193-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS KRAS, HRAS, NRAS FABP5 4631/4885FABP7 4721/4885KMT2A 1250/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS FABP5 4094/4885FABP7 4602/4885KMT2A 3145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.